Topics

Tecentriq® Improves Survival in Newly Diagnosed or Recurrent NSCLC

04:32 EDT 9 Oct 2019 | Cancer Connect

Tecentriq® Improves NSCLC survival when combined with Avastin & chemotherapy Regardless of PD-L1 Status.

Original Article: Tecentriq® Improves Survival in Newly Diagnosed or Recurrent NSCLC

NEXT ARTICLE

More From BioPortfolio on "Tecentriq® Improves Survival in Newly Diagnosed or Recurrent NSCLC"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...